Your browser is no longer supported. Please, upgrade your browser.
Settings
APVO Aptevo Therapeutics Inc. daily Stock Chart
APVO [NASD]
Aptevo Therapeutics Inc.
Index- P/E- EPS (ttm)-1.44 Insider Own3.70% Shs Outstand44.50M Perf Week-2.03%
Market Cap27.90M Forward P/E- EPS next Y-0.72 Insider Trans32.27% Shs Float38.28M Perf Month-4.30%
Income-49.50M PEG- EPS next Q-0.23 Inst Own38.50% Short Float4.88% Perf Quarter-7.71%
Sales29.70M P/S0.94 EPS this Y-56.10% Inst Trans-11.44% Short Ratio5.56 Perf Half Y-23.28%
Book/sh0.44 P/B1.42 EPS next Y34.30% ROA-64.40% Target Price6.17 Perf Year-69.41%
Cash/sh- P/C- EPS next 5Y- ROE-153.40% 52W Range0.49 - 2.15 Perf YTD-50.63%
Dividend- P/FCF- EPS past 5Y2.00% ROI-104.00% 52W High-71.16% Beta2.58
Dividend %- Quick Ratio0.80 Sales past 5Y167.00% Gross Margin38.60% 52W Low26.53% ATR0.05
Employees118 Current Ratio1.00 Sales Q/Q55.20% Oper. Margin- RSI (14)49.83 Volatility9.19% 7.97%
OptionableYes Debt/Eq1.00 EPS Q/Q59.30% Profit Margin- Rel Volume0.18 Prev Close0.63
ShortableYes LT Debt/Eq0.00 EarningsNov 13 AMC Payout- Avg Volume335.48K Price0.62
Recom1.70 SMA20-1.74% SMA501.21% SMA200-20.18% Volume41,940 Change-1.12%
Nov-05-18Initiated Ladenburg Thalmann Buy
Oct-05-17Resumed Piper Jaffray Overweight $6
Dec-06-19 09:00AM  Aptevo Therapeutics Receives Orphan Drug Designation for APVO436 for the Treatment of Acute Myelogenous Leukemia GlobeNewswire
Nov-12-19 09:00AM  What Makes Aptevo Therapeutics Inc. (APVO) a New Buy Stock Zacks
Nov-08-19 09:00AM  Aptevo Therapeutics and Alligator Bioscience Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting GlobeNewswire +7.39%
Nov-07-19 09:00AM  Aptevo Therapeutics Reports Third Quarter 2019 Financial Results GlobeNewswire
Oct-04-19 07:32AM  The Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid Offering Benzinga +6.93%
Oct-03-19 04:02PM  Aptevo Therapeutics Provides Corporate and Pipeline Update Globenewswire Test
04:02PM  Aptevo Therapeutics Provides Corporate and Pipeline Update GlobeNewswire
Sep-19-19 09:00AM  Aptevo Therapeutics Introduces New Adaptir Bispecific Antibody Candidate Intended for the Treatment of Solid Tumors GlobeNewswire
Aug-09-19 09:00AM  Aptevo Therapeutics Reports Second Quarter 2019 Financial Results GlobeNewswire -9.67%
Aug-07-19 09:02AM  Aptevo Therapeutics Receives $4.3 Million Milestone Payment From Saol International Limited GlobeNewswire
Jul-25-19 04:32PM  Aptevo Therapeutics Reports Continued Progress In APVO210 and APVO436 Clinical Trials GlobeNewswire
Jun-25-19 09:00AM  Aptevo Therapeutics Launches New 3000 IU IXINITY Assay Offering Enhanced User Experience and Improved Convenience for Hemophilia B Patients GlobeNewswire -5.99%
May-09-19 09:00AM  Aptevo Therapeutics Reports First Quarter 2019 Financial Results GlobeNewswire
Apr-29-19 10:21AM  The Zacks Analyst Blog Highlights: Advanced Emissions, Aptevo, BankFinancial, Good Times and Health Insurance Zacks
Apr-26-19 08:31AM  5 Stocks to Gain From Dollar's Recent Strength Zacks
Apr-15-19 09:00AM  Aptevo Therapeutics Reports IXINITY® and Pipeline Progress GlobeNewswire
Apr-11-19 12:26PM  What Kind Of Investor Owns Most Of Aptevo Therapeutics Inc. (NASDAQ:APVO)? Simply Wall St.
Apr-02-19 09:02AM  Aptevo Therapeutics Presents New Preclinical Data for APVO436 and ALG.APV-527 at the American Association for Cancer Research 2019 Annual Meeting GlobeNewswire
Mar-25-19 09:02AM  Aptevo Therapeutics to Present New Preclinical Data for APVO436 and ALG.APV.527 at the American Association for Cancer Research 2019 Annual Meeting GlobeNewswire +6.67%
Mar-20-19 09:02AM  Aptevo Therapeutics Begins Phase 1 Clinical Trial of APVO210 a Novel Bispecific Antibody for the Treatment of Autoimmune and Inflammatory Diseases GlobeNewswire
Mar-18-19 09:00AM  Aptevo Therapeutics Reports 2018 Financial Results and Provides Business Update GlobeNewswire +6.10%
Mar-14-19 10:28AM  Aptevo Therapeutics Inc. (APVO) Moves to Buy: Rationale Behind the Upgrade Zacks
Mar-07-19 09:13AM  Aptevo Announces Pricing of $22 Million Offering of Common Stock and Warrants GlobeNewswire -40.20%
Mar-06-19 04:37PM  Aptevo Announces Proposed Public Offering of Common Stock and Warrants GlobeNewswire +5.71%
Jan-07-19 08:30AM  Aptevo Therapeutics Highlights Key 2019 Priorities GlobeNewswire
Jan-03-19 09:02AM  Aptevo Therapeutics Collects $3.3 Million In Escrow Funds From Saol Therapeutics GlobeNewswire
Dec-21-18 09:00AM  Aptevo Therapeutics Announces Up To $35 Million Common Stock Purchase Agreement With Lincoln Park Capital GlobeNewswire -9.29%
Dec-20-18 12:57PM  Need To Know: Aptevo Therapeutics Inc. (NASDAQ:APVO) Insiders Have Been Buying Shares Simply Wall St. -11.95%
Dec-13-18 09:02AM  Aptevo Therapeutics Doses First Patient in Phase 1/1b Clinical Trial of Lead Next-Generation Bispecific Antibody APVO436 GlobeNewswire -6.98%
Dec-11-18 07:20AM  United Parcel Service, Endurance International Group, Idera Pharmaceuticals, Aptevo Therapeutics, and Electro Scientific Industries Future Expectations, Projections Moving into 2018 GlobeNewswire
Nov-20-18 09:00AM  Aptevo Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-14-18 04:02PM  Aptevo Therapeutics Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-09-18 12:00AM  Alligator Bioscience and Aptevo Therapeutics Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting GlobeNewswire -5.88%
Oct-24-18 09:00AM  Aptevo Therapeutics Announces Expanded Growth Initiatives for IXINITY GlobeNewswire -12.88%
Oct-10-18 08:40AM  Market Trends Toward New Normal in Aptevo Therapeutics, Bottomline Technologies, Allete, Air Lease, The Goodyear Tire & Rubber, and EastGroup Properties Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Sep-25-18 11:29AM  Aptevo Therapeutics to Present at the Ladenburg Thalmann 2018 Healthcare Conference GlobeNewswire
Sep-05-18 11:36AM  Here's Why Momentum Investors Will Love Aptevo Therapeutics Inc. (APVO) Zacks
Aug-31-18 02:46PM  Penny Stocks to Buy Using Technical Analysis for September 2018 Investopedia
Aug-09-18 09:00AM  Aptevo Therapeutics Reports Second Quarter 2018 Financial Results GlobeNewswire
Aug-07-18 09:00AM  Aptevo Therapeutics Revises Term Loan Agreement With MidCap Financial; Reduces Cash Requirements by $18 Million GlobeNewswire
Aug-06-18 08:10AM  Report: Developing Opportunities within athenahealth, W.R. Berkley, Air Products and Chemicals, DICK'S Sporting Goods, Aptevo Therapeutics, and Columbia Property Trust Future Expectations, Projections Moving into 2018 GlobeNewswire
May-29-18 09:00AM  Novel First-In-Class Immunotherapeutic APVO210 Features Unique Mechanism of Action Delivering IL-10 GlobeNewswire
May-15-18 07:40AM  Wired News Arrowhead Pharma Presented Preclinical Data on Expanding Pipeline of RNAi Therapeutics for Cardiometabolic Diseases ACCESSWIRE +17.10%
May-10-18 09:00AM  Aptevo Therapeutics Reports First Quarter 2018 Financial Results GlobeNewswire +14.22%
May-08-18 09:02AM  New Preclinical Data for Novel Immunotherapy Bispecific Candidate ALG.APV-527 Presented by Aptevo Therapeutics and Alligator Bioscience at Prominent Industry Conferences GlobeNewswire
May-01-18 09:00AM  Aptevo Therapeutics Announces IND Submission for APVO436 GlobeNewswire
Apr-30-18 07:50AM  Report: Developing Opportunities within Natus Medical, Aptevo Therapeutics, Revlon, Silgan, Resources Connection, and TrustCo Bank Corp NY Future Expectations, Projections Moving into 2018 GlobeNewswire
Apr-20-18 08:35PM  Aptevo executive Jane Gross jumped to a startup and landed in the C-Suite American City Business Journals
Apr-16-18 09:02AM  Aptevo Therapeutics Bispecific Antibody APVO436 Shows Robust T-Cell Activation With Minimal Cytokine Release GlobeNewswire +17.99%
Mar-19-18 08:20AM  Research Report Identifies Ambarella, Merit Medical, NETGEAR, Independent Bank, Cutera, and Aptevo Therapeutics with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Mar-13-18 09:02AM  Aptevo Therapeutics Reports 2017 Financial Results and Provides Business Update GlobeNewswire
Mar-12-18 09:02AM  Aptevo Therapeutics Presents New Patient-Reported Data With IXINITY GlobeNewswire
Feb-27-18 09:02AM  Aptevo Therapeutics to Present at the 30th Annual ROTH Conference GlobeNewswire
Jan-17-18 08:10AM  Report: Exploring Fundamental Drivers Behind Anthera Pharmaceuticals, Alarm, Aptevo Therapeutics, Shoe Carnival, Independent Bank, and First Internet New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire +10.02%
Jan-11-18 09:04AM  How Is Bioverativs Alprolix Positioned Now? Market Realist
Jan-08-18 09:00AM  Aptevo Therapeutics Begins Patient Dosing in Phase 2 Clinical Trial of Otlertuzumab in Peripheral T-Cell Lymphoma GlobeNewswire -8.55%
Jan-03-18 08:17AM  Aptevo Therapeutics, Inc. :APVO-US: Earnings Analysis: Q3, 2017 By the Numbers : January 3, 2018 Capital Cube
Dec-27-17 10:58AM  ETFs with exposure to Aptevo Therapeutics, Inc. : December 27, 2017 Capital Cube
Dec-19-17 09:05AM  Does Aptevo Therapeutics Incs (NASDAQ:APVO) 74.9% EPS Growth Reflect The Long-Term Trend? Simply Wall St.
Dec-11-17 01:28PM  ETFs with exposure to Aptevo Therapeutics, Inc. : December 11, 2017 Capital Cube -5.67%
09:02AM  Aptevo Therapeutics Novel Bispecific Antibody Therapeutic APVO436 Shows Broad Activity in Primary Human AML Samples GlobeNewswire
Nov-29-17 10:58AM  ETFs with exposure to Aptevo Therapeutics, Inc. : November 29, 2017 Capital Cube
Nov-28-17 07:02AM  Aptevo Therapeutics Announces Plans to Conduct Phase 2 Study of Otlertuzumab in Peripheral T-Cell Lymphoma GlobeNewswire
Nov-21-17 06:39PM  Is Aptevo Therapeutics Incs (APVO) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
Nov-14-17 04:02PM  Aptevo Therapeutics to Present at the 29th Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-09-17 04:30PM  Aptevo Therapeutics Reports Third Quarter 2017 Financial Results GlobeNewswire
Nov-01-17 11:50AM  ETFs with exposure to Aptevo Therapeutics, Inc. : November 1, 2017 Capital Cube
Oct-30-17 09:02AM  Aptevo Therapeutics Presents New Preclinical Data on APVO436 a Next Generation ADAPTIR Bispecific Antibody Candidate GlobeNewswire
Oct-24-17 09:00AM  Tumor Antigen 5T4 Associated With Many Forms of Solid Tumors Identified as the Second Target for ALG.APV-527 a Novel Bispecific Antibody Candidate Being Developed by Alligator Bioscience and Aptevo Therapeutics GlobeNewswire
Oct-16-17 09:02AM  Aptevo Therapeutics Showcases New Mechanism of Action for Its ADAPTIR Platform at the Inflammation Research Society Meeting GlobeNewswire
Oct-10-17 08:31AM  Aptevo Therapeutics, Analyst Coverage, ADAPTIR Platform and Recent Drug Asset Sale ACCESSWIRE
Oct-06-17 10:37AM  ETFs with exposure to Aptevo Therapeutics, Inc. : October 6, 2017 Capital Cube
Oct-02-17 09:00AM  Aptevo Therapeutics Presents New Data on Enhanced Features of Its Next Generation ADAPTIR Bispecific Platform at the World Bispecific Summit GlobeNewswire
Sep-28-17 04:45PM  Aptevo Therapeutics Extends Cash Runway $20 Million; Retains Term Loan Agreement With MidCap Financial GlobeNewswire
04:35PM  Aptevo Therapeutics Completes Sale of Hyperimmune Products for Up to $74.5 Million GlobeNewswire
Aug-31-17 05:17PM  ETFs with exposure to Aptevo Therapeutics, Inc. : August 31, 2017 Capital Cube
05:16PM  Aptevo Therapeutics Signs Agreement for Up to $74.5 Million to Sell Hyperimmune Commercial Products GlobeNewswire
05:15PM  Aptevo Therapeutics and MorphoSys End Joint Development and Commercialization Agreement for MOR209/ES414 GlobeNewswire
Aug-25-17 11:29AM  Aptevo Therapeutics, Inc. :APVO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017 Capital Cube
Aug-17-17 07:00AM  Aptevo Therapeutics and Alligator Bioscience Commence IND-Enabling Development Activities for New Bispecific Immunotherapy Candidate ALG.APV-527 GlobeNewswire
Aug-10-17 09:02AM  Aptevo Therapeutics Reports Second Quarter 2017 Financial Results GlobeNewswire
Aug-01-17 04:12PM  ETFs with exposure to Aptevo Therapeutics, Inc. : August 1, 2017 Capital Cube
Jul-20-17 05:20PM  Aptevo Therapeutics and Alligator Bioscience Announce Plans to Co-Develop Novel Bispecific Antibody for Tumor-Directed Immunotherapy GlobeNewswire
03:10PM  Emergent BioSolutions acquires GlaxoSmithKline anthrax drug for $96 million American City Business Journals
Jul-07-17 02:27PM  ETFs with exposure to Aptevo Therapeutics, Inc. : July 7, 2017 Capital Cube
Jun-07-17 09:02AM  Aptevo Therapeutics Highlights Key Features of Its ADAPTIR Protein Therapeutic Platform at Two Industry Conferences GlobeNewswire
Jun-05-17 02:00PM  ETFs with exposure to Aptevo Therapeutics, Inc. : June 5, 2017 Capital Cube
Jun-02-17 10:32AM  Aptevo Therapeutics, Inc. :APVO-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube
May-12-17 09:02AM  Aptevo Therapeutics Reports First Quarter 2017 Financial Results GlobeNewswire
May-05-17 09:02AM  Aptevo Therapeutics Presents Detailed Overview of its Adaptir Protein Therapeutic Platform at the 13th Annual Pegs Summit GlobeNewswire
Apr-28-17 03:40PM  ETFs with exposure to Aptevo Therapeutics, Inc. : April 28, 2017 Capital Cube
Apr-10-17 01:41PM  ETFs with exposure to Aptevo Therapeutics, Inc. : April 10, 2017 Capital Cube
09:00AM  Aptevo Therapeutics Presents New Clinical Data Evaluating the Safety and Efficacy of IXINITY in Children With Hemophilia B GlobeNewswire
Apr-07-17 02:58PM  Aptevo Therapeutics, Inc. :APVO-US: Earnings Analysis: Q4, 2016 By the Numbers : April 7, 2017 Capital Cube
12:28PM  Aptevo Therapeutics, Inc. :APVO-US: Earnings Analysis: 2016 By the Numbers : April 7, 2017 Capital Cube
Apr-03-17 09:03AM  Aptevo Therapeutics Next Generation ADAPTIR Bispecific Antibody Candidates Show Potent Immune Activation GlobeNewswire
Mar-31-17 09:42AM  APTEVO THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Non-Reliance on Previous
09:00AM  Aptevo Therapeutics Reports 2016 Financial Results and Provides Business Update GlobeNewswire
Mar-15-17 08:30AM  Aptevo Therapeutics Announces New IXINITY Supply Available May 2017 GlobeNewswire
Mar-14-17 09:25AM  Aptevo Therapeutics Expands Bispecific Antibody Portfolio GlobeNewswire
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its investigational stage product candidates comprise APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute myeloid leukemia and high-grade myelodysplastic syndrome; APVO210, an anti-inflammatory molecule that is in pre-clinical development stage for the treatment of autoimmune and inflammatory diseases; ALG.APV-527, a bispecific antibody to target T cells; ROR1 Bispecific, a proof-of-concept bispecific candidate that is in preclinical development; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Maddux Randy JoeSVP Operations, CMOAug 16Buy0.7625,00019,00075,000Aug 19 08:29 AM
El-Hibri FuadDirectorAug 12Buy0.76100,00075,5201,124,536Aug 13 09:46 PM
El-Hibri FuadBoard of DirectorsJul 29Buy0.8355,01545,8611,024,536Jul 30 06:49 PM
El-Hibri FuadBoard of DirectorsJul 23Buy0.9010,0008,996969,521Jul 24 06:49 PM
El-Hibri FuadBoard of DirectorsJul 22Buy0.8930,00026,601959,521Jul 23 04:19 PM
El-Hibri FuadBoard of DirectorsJul 19Buy0.9026,46023,740929,521Jul 19 06:18 PM
El-Hibri FuadBoard of DirectorsJul 18Buy0.8714,40412,596903,061Jul 18 05:12 PM
El-Hibri FuadBoard of DirectorsJul 17Buy0.8719,13616,704888,657Jul 18 04:50 PM
El-Hibri FuadBoard of DirectorsJul 16Buy0.8511,3759,662869,521Jul 16 05:54 PM
El-Hibri FuadBoard of DirectorsJul 11Buy0.8514,69112,454858,146Jul 12 12:41 PM
El-Hibri FuadDirectorJul 10Buy0.8518,91916,058843,455Jul 11 04:10 PM
Abdun-Nabi DanielBoard of DirectorsJun 25Buy0.9016,66715,000109,351Jun 25 07:11 PM
White Marvin LPresident and CEOJun 14Buy0.8850,00044,000293,603Jun 14 01:58 PM
Kunz Barbara LopezBoard of DirectorsJun 10Buy0.8510,0008,48110,000Jun 11 02:57 PM
Harsanyi ZsoltBoard of DirectorsJun 07Buy0.7850,00039,00050,000Jun 07 03:19 PM
Maddux Randy JoeSenior VP, OperationsMay 31Buy0.7320,00014,60050,000Jun 07 03:18 PM
Grant Grady IIIBoard of DirectorsMay 21Buy0.8010,0007,97010,000May 21 06:12 PM
White Marvin LPresident and CEOMay 20Buy0.8130,00024,300243,603May 20 07:22 PM
White Marvin LPresident and CEOMay 14Buy0.7810,0007,800213,603May 14 09:27 PM